The cardiorenal connection and diabetes: Exploring intervention by SGLT2i
Video navigation menu
- Effects of SGLT2 inhibitors 00:21
- SGLT2 function in the early proximal tubule 01:32
- SGLT2i and BP effects: changes in intravascular volume 05:38
- Potential mechanisms of SGLT2i 07:34
- Clinical trials with SGLT2i 10:09
What is the potential mechanism of blood pressure lowering by SGLT2i?
- A. Decrease in red cell mass
- B. Decrease in plasma volume
- C. Increase in fluid retention by the interstitial compartment
- D. Increase in skin sodium content
This lecture by Maria Rosa Costanzo was part of the EBAC-accredited symposium "Impacting cardiovascular and kidney protection in CKD: The evolving role of SGLT2i" held during the virtual ERA EDTA 2020 meeting.
Maria Rosa Costanzo, MD is a cardiologist and medical director for heart failure research at the Advocate Heart Institute in Naperville, IL, USA.
This recording was independently developed under auspices of PACE-cme. The views expressed in this recording are those of the individual presenter and do not necessarily reflect the views of PACE-cme.
Funding for this educational program was provided by an unrestricted educational grant from Boehringer Ingelheim/Lilly.
The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.
Share this page with your colleagues and friends: